特布他林和布地奈德联合雾化吸入治疗咳嗽变异性哮喘临床疗效研究.docVIP

特布他林和布地奈德联合雾化吸入治疗咳嗽变异性哮喘临床疗效研究 　　摘要：目的：观察特布他林联合布地奈德雾化吸入治疗变异性哮喘（CAV）的临床疗效。方法：2012年1月至2014年1月80例变异性哮喘患儿随机分两组，对照组40例采用常规治疗，观察组40例在常规治疗的基础上给予特布他林联合布地奈德雾化吸入治疗，观察两组临床疗效及临床症状的变化。结果：观察组的总有效率90%，明显高于对照组65%（p〈0.05），观察组患儿症状消退时间及平均住院时间均明显短于对照组（p〈0.05）；两组不良反应均较轻微。结论：特布他林与布地奈德联合雾化吸入法治疗小儿变异性哮喘有助于改善CVA患者肺功能，减少咳嗽发作，疗效好、见效快、不良反应少等诸多优点，并可减少CVA发展典型支气管哮喘的概率，可作为咳嗽变异性哮喘的一种较佳治疗方案。 　　关键词：咳嗽变异性哮喘 特布他林 布地奈德 雾化吸入 　　Abstract：Objective： To observe the clinical efficacy of Terbutaline associated with Budesonide atomization inhalation treatment on cough variant asthma（CVA）. Methods： 80 cases of children with variant asthma during Jan，2012 and Jan，2014 were devided into two groups randomly， 40 cases in the control group with conventional treatment， while observation group， 40 patients were given terbutaline and budesonide inhalation therapy on the basis of conventional therapy， and then observe the changes on clinical efficacy and clinical symptoms between these two groups. Results： the total efficiency of the observation group is 90%， obviously higher than the control group of 65% （p〈0.05）， the time of symptoms subsiding and The average length of hospital stay on children in observation group is significantly shorter than the control group （p 0.05）； Two groups of adverse reactions are mild. Conclusion： using terbutaline with budesonide atomization inhalation method treatment on variant asthma children helps improve lung function in patients with CVA， reduce coughing episodes， and it has many advantages， like good curative effect， quick effect， less adverse reactions， and it can reduce the probability of the development of typical bronchial asthma as a preferred treatment regimen on cough variant asthma. 　　Keywords： Cough Variant Asthma； Terbutaline ； Budesonide ； Inhalation 　　咳嗽变异性哮喘（cough variant asthma ，CVA）又称为过敏性哮喘、隐匿性性哮喘、咳嗽性哮喘，是以慢性咳嗽为主要临床表现的一种哮喘的潜在形式，伴或不伴有轻微胸闷或喘息（1）。CAV的发病机制至今尚不完全清楚，多数西医学者认为本病是由多种细胞特别是肥大细胞、嗜酸性粒细胞的T淋巴细胞参与的气道慢性炎症，引起气道高反应，导致可逆性气道阻塞，除此之外还有与变态反应、遗传以及神经免疫等因素相互作用有关。临床表现为持续性或慢性咳